Revolymer gets approval for great tasting environmentally friendly nicotine gum

Canadians will pioneer the gum that uses new technology to mask the nicotine taste ahead of
global rollout

Revolymer® Ltd, the revolutionary polymer company behind REV7 degradable gum, is pleased to
announce approval by the Natural Health Products Directorate of Canada for the sale of a new
generation of nicotine gum. Distributed in Canada by sales and marketing partner, SDS Pharma, this approval is the first step in Revolymer®’s global strategy in functional gums to release a nicotine gum that not only helps smokers quit but also offers a great chew.

Third parties who evaluated the product found it superior in taste and texture to any current generic nicotine gums, and as it lacks the bitter taste of many commercial nicotine gums, it should further help smokers in their quest to quit smoking. Moreover, an additional benefit to ex smokers is that in house tests have shown that the product will whiten teeth as it is chewed.

The current market for nicotine chewing gum now totals $1.6bn world-wide, yet there has been little innovation of the product over the last 20 years. Many smokers who try to quit using gum are put off by the taste of the existing products. Revolymer® has applied its proprietary technology which not only controls the release of nicotine but also helps to mask its bitter taste through molecular encapsulation. The product has been scaled up by a manufacturing partner with 2.5 million pieces of gum made in both 2 and 4 mg doses with flavours of spearmint, peppermint and fresh fruit .

“Over the past year, we have been applying our environmentally friendly chewing gum technology to functional chewing gums and our first goal was to develop a nicotine gum with an improved taste to help people to quit smoking” said Roger Pettman, Chairman and Chief Executive Officer of Revolymer®.

“Achieving regulatory approval so quickly is another key milestone for Revolymer® and I am also delighted to be working closely with Greg and the team at SDS Pharma”.

Greg Kelly, President of SDS Pharma added, “We at SDS Pharma Partners are very excited to be
working with Revolymer® on the introduction of new nicotine replacement gums to Canada.

Consumer and customer responses have demanded improved taste and a more pleasant mouth-feel
versus the currently marketed products. Revolymer® meets and exceeds those demands and the
resulting user experience is superb.

One of our key goals is bringing innovative new products to the Canadian marketplace, and
delivering superior sales and profit to the retail trade. The Canadian market for nicotine chewing gum is the fourth biggest in the world and Canadians chew more than 120 million pieces a year, so we look forward to establishing Revolymer® as a valued supplier in Canada and expanding their presence with innovative solutions.”